CAR T-Cell Immunotherapy and Future Treatment Applications for Brain Tumor Patients

Dr. Charles Cobbs, Neurosurgeon and Director of The Ben and Catherine Ivy Center for Advanced Brain Tumor Treatment at Swedish Neuroscience Institute in Seattle discusses CAR T-cell immunotherapy and its application to Brain Tumor treatment. For additional articles on this recent research for brain tumor patients, here are some additional links: https://www.cancer.gov/about-cancer/treatment/research/car-t-cells http://www.onclive.com/publications/contemporary-oncology/2014/august-2014/chimeric-antigen-receptor-car-t-cell-immunotherapy-for-leukemia-and-beyond https://www.cirm.ca.gov/agendas/02192015/car-t-cell-immunotherapy-challenges-and-opportunities-using-mature-or-stem-memory-t

Immunocellular Therapeutics

Immunocellular Therapeutics Phase 3 ICT 107 Vaccine Clinical Trial for Glioblastoma Patients

ICT 107 is a vaccine for glioblastoma cancer stem cells.  This vaccine was developed by a company called ImmunoCellular Therapeutics, (https://www.imuc.com ) primarily by researchers at Cedars Sinai in Los Angeles.  https://virtualtrials.com/newsarticle.cfm?item=6107  This protocol has completed phase II testing and now it is open to a phase 3 randomized double blind control study for newly diagnosed glioblastoma.  […]